BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS
BERGEN, Norway, September 27, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Oslo University Hospital announced today that the first patient has been included in a study of BerGenBio’s oral, highly selective AXL inhibitor, bemcentinib, as part of the EU-SolidAct trial in hospitalized COVID-19 patients. The EU-SolidAct trial (European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial) is part of EU-RESPONSE, a pan-European research